{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:58:31Z","timestamp":1772780311594,"version":"3.50.1"},"reference-count":17,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2007,8,23]],"date-time":"2007-08-23T00:00:00Z","timestamp":1187827200000},"content-version":"vor","delay-in-days":5013,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Psychiatr Scand"],"published-print":{"date-parts":[[1993,12]]},"abstract":"<jats:p>Risperidone (RIS), a new neuroleptic with 5\u2010HT<jats:sub>2<\/jats:sub>\u2010 and dopamine D<jats:sub>2<\/jats:sub> receptor\u2010blocking properties, was compared with perphenazine (PER) in a double\u2010blind, multicentre, parallel\u2010group study in 107 chronic schizophrenics with acute exacerbation. RIS 5\u201015 mg or PER 16\u201348 mg daily was given for 8 weeks. Psychopathology was assessed with the Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression. Seventy\u2010eight patients completed the trial; there was an equal number of dropouts on both drugs. The mean daily dose at endpoint was 8.5 mg RIS and 28 mg PER. The reduction in total PANSS score to endpoint did not differ significantly, although there was a tendency in favour of RIS. The number of patients with predominantly negative symptoms who showed at least 20% reduction in total PANSS score was significantly larger in the RIS group. Furthermore, the number of patients showing at least 20% reduction in Brief Psychiatric Rating Scale (BPRS) score (BPRS being a subscale of PANSS) was significantly larger in the RIS group. The hostility cluster of BPRS improved more on RIS than on PER in the endpoint analysis. The overall prevalence of side effects was fairly similar in the two groups.<\/jats:p>","DOI":"10.1111\/j.1600-0447.1993.tb03480.x","type":"journal-article","created":{"date-parts":[[2007,8,23]],"date-time":"2007-08-23T12:47:55Z","timestamp":1187873275000},"page":"395-402","source":"Crossref","is-referenced-by-count":120,"title":["Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations"],"prefix":"10.1111","volume":"88","author":[{"given":"O. J.","family":"H\u00f8yberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Fensbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Lingj\u00e6rde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Sloth\u2010Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Salvesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Remvig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,8,23]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"661","article-title":"The biochemical profile of risperidone, a new antipsychotic","volume":"247","author":"Leysen JE.","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_3_2","first-page":"685","article-title":"Pharmacology of risperidone (R 64 766). a new antipsychotic with serotonin\u2010S2 and dopamine D2 antagonistic properties","volume":"1988","author":"Janssen PAJ.","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00172961"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.430170104"},{"key":"e_1_2_1_6_2","first-page":"233","article-title":"Risperidone (R 64 766) in psychotic patients: a first clinical therapeutic exploration","volume":"88","author":"Roose K.","year":"1988","journal-title":"Acta Psychiatr Belg"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1014509"},{"key":"e_1_2_1_8_2","volume-title":"Risperidone versus haloperidol in psychotic patients: a multicentre double\u2010blind comparative study. I. Clinical report","author":"Heylen SLE.","year":"1988"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1992.tb01473.x"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(88)90038-8"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.2466\/pr0.1962.10.3.799"},{"issue":"3","key":"e_1_2_1_12_2","first-page":"233","article-title":"The Extrapyramidal Symptoms Rating Scale","volume":"7","author":"Chouinard G.","year":"1980","journal-title":"Can J Neurol Sci"},{"issue":"334","key":"e_1_2_1_13_2","first-page":"81","article-title":"The UKU Side Effect Rating Scale","volume":"76","author":"Lingj\u00e6rde O.","year":"1987","journal-title":"Acta Psychiatr Scand"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0920-9964(89)90034-0"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00589890"},{"issue":"5","key":"e_1_2_1_16_2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1192\/S0007125000295950","article-title":"Thymosthenic agents, a novel approach in the treatment of schizophrenia","volume":"155","author":"Gelder YG.","year":"1989","journal-title":"Br J Psychiatry"},{"key":"e_1_2_1_17_2","first-page":"876","article-title":"Risperidone in the treatment of chronic schizophrenia with tardive dyskinesia: a single\u2010blind crossover study versus placebo","volume":"46","author":"Meco G.","year":"1989","journal-title":"Curr Ther Res"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/hup.470050307"}],"container-title":["Acta Psychiatrica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0447.1993.tb03480.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0447.1993.tb03480.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T02:41:30Z","timestamp":1698201690000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0447.1993.tb03480.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993,12]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1993,12]]}},"alternative-id":["10.1111\/j.1600-0447.1993.tb03480.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0447.1993.tb03480.x","archive":["Portico"],"relation":{},"ISSN":["0001-690X","1600-0447"],"issn-type":[{"value":"0001-690X","type":"print"},{"value":"1600-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[1993,12]]}}}